Waters Corporation (WAT) 10-K Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2000. Waters Corporation is a holding company owning Waters Technologies Corporation, the world's largest manufacturer and distributor of high performance liquid chromatography (HPLC) instruments, columns, and related services. The company also leads in mass spectrometry (via Micromass) and thermal analysis (via TA Instruments). Approximately 64% of net sales in 2000 were derived from the pharmaceutical industry, and 57% of sales were generated outside the United States.
Key Financial Metrics
Note: Specific revenue, profit, cash flow, and debt figures are not provided in the text of this filing. The document explicitly incorporates these values by reference to the 2000 Annual Report to Stockholders (pages 19-23 and 25-45).
- Research & Development (R&D): $42.5 million for fiscal year 2000 (up from $36.1 million in 1999).
- Allowance for Doubtful Accounts: Ended 2000 at $2,815,000.
- Stock Split: A two-for-one stock split was executed in August 2000.
- Market Value: As of March 19, 2001, the aggregate market value of non-affiliate common stock was approximately $6.2 billion.
- Dividends: The company has not declared or paid dividends in the past two years and does not plan to do so in the foreseeable future.
Material Changes and Operational Highlights
- R&D Growth: R&D expenditures increased by approximately 17.7% compared to 1999, reflecting continued investment in product development.
- Capital Structure: Authorized common stock was increased from 100 million to 200 million shares, approved by shareholders in May 2000.
- Facility Expansion: Construction is underway for 35,000 additional square feet of space in Manchester, England, scheduled for occupancy in spring 2001.
- Customer Concentration: No single customer accounted for more than 2% of net sales in fiscal 2000, indicating a diversified customer base.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The company anticipates growth through new product introductions and acquisitions. However, forward-looking statements are subject to risks including economic conditions, regulatory changes, and the ability to generate sales from new products.
Key Risks:
- Foreign Exchange: Approximately 57% of sales are in foreign currencies; significant strengthening of the U.S. dollar could materially adversely affect results.
- Competition: The analytical instrument market is highly competitive, with competitors possessing greater financial resources.
- Operational Disruption: Manufacturing is concentrated in specific facilities (e.g., Milford, MA; Manchester, England); prolonged disruption could materially impact operations.
- Key Personnel: No key management employees have employment contracts, creating reliance on their continued service.
Legal Proceedings: The company is involved in several patent disputes (including with Perkin-Elmer, Hewlett-Packard, Cohesive Technologies, and Viscotek). Management believes it has meritorious arguments in all cases and does not expect any outcome to be material to the company.
Investor Verification Checklist
- Verify specific revenue, net income, and cash flow figures in the 2000 Annual Report to Stockholders (incorporated by reference), as they are absent from this 10-K text.
- Review the impact of the two-for-one stock split on historical per-share data comparisons.
- Assess the foreign currency exposure given that 57% of sales are international and the potential volatility of the Euro conversion (effective 2002).
- Monitor the status of ongoing patent litigation to ensure no material adverse judgments occur.
- Confirm the company's strategy regarding acquisitions and new product launches as a driver for future growth.